Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription 01.07.2019 2 Am J Clin Oncol 2 Ann Thorac Surg 4 BMC Cancer 1 Br J Cancer 2 Cancer Sci 1 Carcinogenesis 14 Clin Lung Cancer 2 Eur J Cardiothorac Surg 1 J Cancer Res Clin Oncol 3 J Thorac Cardiovasc Surg 6 J Thorac Oncol 1 JAMA Oncol 1 Lung Cancer 1 Lung Cancer (Auckl) 1 Oncogene 5 Oncol Rep 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. NICOLI CD, Sprague BL, Anker CJ, Lester-Coll NH, et al
   Association of Rurality With Survival and Guidelines-Concordant Management in Early-stage Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2019;42:607-614.
   PubMed     Text format     Abstract available
   
   
2. SINGH R, Ansinelli H, Sharma D, Jenkins J, et al
   Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
   Am J Clin Oncol. 2019;42:602-606.
   PubMed     Text format     Abstract available
   
   

   
   Ann Thorac Surg

3. MAMMANA M, Zuin A, Serra E, Bellini A, et al
   Complex lobectomy in a patient with lung cancer and pulmonary artery sling.
   Ann Thorac Surg. 2019 Jun 20. pii: S0003-4975(19)30865.
   PubMed     Text format     Abstract available
   
   
4. NISHIMURA JM, Ansari AZ, D'Souza DM, Moffatt-Bruce SD, et al
   Computed Tomography-Assessed Skeletal Muscle Mass as a Predictor of Outcomes in Lung Cancer Surgery.
   Ann Thorac Surg. 2019 Jun 19. pii: S0003-4975(19)30855.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

5. KLEMENT RJ, Abbasi-Senger N, Adebahr S, Alheid H, et al
   The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
   BMC Cancer. 2019;19:173.
   PubMed     Text format     Abstract available
   
   
6. KANG N, Choi SY, Kim BN, Yeo CD, et al
   Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation.
   BMC Cancer. 2019;19:148.
   PubMed     Text format     Abstract available
   
   
7. NAMBA K, Tomida S, Matsubara T, Takahashi Y, et al
   Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naive lung adenocarcinoma.
   BMC Cancer. 2019;19:175.
   PubMed     Text format     Abstract available
   
   
8. GE M, Zhan Q, Zhang Z, Ji X, et al
   Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
   BMC Cancer. 2019;19:143.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

9. MORGENSZTERN D, Rose M, Waqar SN, Morris J, et al
   RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.
   Br J Cancer. 2019 Jun 24. pii: 10.1038/s41416-019-0504.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Sci

10. LIANG W, Guo M, Pan Z, Cai X, et al
    Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition.
    Cancer Sci. 2019;110:2014-2021.
    PubMed     Text format     Abstract available
    
    
11. LI X, Zhu J, Liu Y, Duan C, et al
    MicroRNA-331-3p inhibits epithelial-mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/beta-catenin axis in non-small-cell lung cancer.
    Cancer Sci. 2019;110:1883-1896.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

12. YEUNG YT, Fan S, Lu B, Yin S, et al
    CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction.
    Carcinogenesis. 2019 Jun 25. pii: 5523300. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

13. CASIRAGHI M, Guarize J, Sandri A, Maisonneuve P, et al
    Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?
    Clin Lung Cancer. 2019;20:97-106.
    PubMed     Text format     Abstract available
    
    
14. FODOR A, Broggi S, Incerti E, Dell'Oca I, et al
    Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
    Clin Lung Cancer. 2019;20:e29-e38.
    PubMed     Text format     Abstract available
    
    
15. LAM VK, Tran HT, Banks KC, Lanman RB, et al
    Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
    Clin Lung Cancer. 2019;20:30-36.
    PubMed     Text format     Abstract available
    
    
16. HU F, Xu J, Zhang B, Li C, et al
    Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
    Clin Lung Cancer. 2019;20:e81-e90.
    PubMed     Text format     Abstract available
    
    
17. SCOTTI V, Bruni A, Francolini G, Perna M, et al
    Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.
    Clin Lung Cancer. 2019;20:e53-e61.
    PubMed     Text format     Abstract available
    
    
18. ZHU YC, Wang WX, Zhang QX, Xu CW, et al
    The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
    Clin Lung Cancer. 2019;20:e73-e76.
    PubMed     Text format    
    
    
19. WANG S, Hao J, Qian C, Wang H, et al
    Tumor Spread Through Air Spaces Is a Survival Predictor in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2019 May 29. pii: S1525-7304(19)30139.
    PubMed     Text format     Abstract available
    
    
20. REN H, Hou X, Eiken PW, Zhang J, et al
    Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.
    Clin Lung Cancer. 2019;20:e142-e147.
    PubMed     Text format    
    
    
21. PASSARO A, Prelaj A, Bonanno L, Tiseo M, et al
    Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.
    Clin Lung Cancer. 2019;20:e186-e194.
    PubMed     Text format     Abstract available
    
    
22. ROTOW JK, Woodard GA, Urisman A, McCoach CE, et al
    Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
    Clin Lung Cancer. 2019;20:e137-e141.
    PubMed     Text format    
    
    
23. WU T, Zhou F, Soodeen-Lalloo AK, Yang X, et al
    The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
    Clin Lung Cancer. 2019;20:e195-e207.
    PubMed     Text format     Abstract available
    
    
24. NIKITAS J, DeWees T, Rehman S, Abraham C, et al
    Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers.
    Clin Lung Cancer. 2019;20:107-116.
    PubMed     Text format     Abstract available
    
    
25. JIANG Y, Liu LS, Shen LP, Liu JX, et al
    Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Clin Lung Cancer. 2019 May 21. pii: S1525-7304(19)30138.
    PubMed     Text format     Abstract available
    
    
26. KAUFFMANN-GUERRERO D, Kahnert K, Kumbrink J, Syunyaeva Z, et al
    Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Clin Lung Cancer. 2019;20:59-62.
    PubMed     Text format    
    
    

    
    Eur J Cardiothorac Surg

27. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    Complex segmentectomy in the treatment of stage IA non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2019 Jun 23. pii: 5522159. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
28. VALO JK, Kyto V, Sipila J, Rautava P, et al
    Thoracoscopic surgery for lung cancer is associated with improved survival and shortened admission length: a nationwide propensity-matched study.
    Eur J Cardiothorac Surg. 2019 Jun 26. pii: 5523684. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

29. TSYGANOV MM, Pevzner AM, Ibragimova MK, Deryusheva IV, et al
    Human papillomavirus and lung cancer: an overview and a meta-analysis.
    J Cancer Res Clin Oncol. 2019 Jun 24. pii: 10.1007/s00432-019-02960.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Cardiovasc Surg

30. MITCHELL KG, Parra ER, Nelson DB, Zhang J, et al
    Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2019 May 17. pii: S0022-5223(19)31015.
    PubMed     Text format     Abstract available
    
    
31. KOZOWER BD
    Commentary: Invasive mediastinal staging for patients with lung cancer-We need to do better!
    J Thorac Cardiovasc Surg. 2019 May 24. pii: S0022-5223(19)31112.
    PubMed     Text format    
    
    
32. FARJAH F, Silvestri GA, Wood DE
    Commentary: Invasive mediastinal staging for lung cancer-Quality gap, evidence gap, both?
    J Thorac Cardiovasc Surg. 2019 May 24. pii: S0022-5223(19)31113.
    PubMed     Text format    
    
    

    
    J Thorac Oncol

33. WANG H, Zhang L, Liu W
    Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e141-e143.
    PubMed     Text format    
    
    
34. CHAE YK, Viveiros P, Lopes G, Sukhadia B, et al
    Clinical and immunological implications of frameshift mutations in lung cancer.
    J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496.
    PubMed     Text format     Abstract available
    
    
35. CANEPA M, Patel NR, Griffith RC, Ng TT, et al
    KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e153-e155.
    PubMed     Text format    
    
    
36. BALATA H, Fong KM, Hendriks LE, Lam S, et al
    Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30476.
    PubMed     Text format     Abstract available
    
    
37. GUO R, Berry LD, Aisner DL, Sheren J, et al
    MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30474.
    PubMed     Text format     Abstract available
    
    
38. HO C, Lefresne S, Liberman M, McGuire A, et al
    Lung Cancer in Canada.
    J Thorac Oncol. 2019;14:1128-1133.
    PubMed     Text format    
    
    

    
    JAMA Oncol

39. ALDRICH MC, Mercaldo SF, Sandler KL, Blot WJ, et al
    Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers.
    JAMA Oncol. 2019 Jun 27. pii: 2737091. doi: 10.1001/jamaoncol.2019.1402.
    PubMed     Text format     Abstract available
    
    

    
    Lung Cancer

40. PARDO-CABELLO AJ, Manzano-Gamero V
    Small cell lung cancer elevates procalcitonin levels in the absence of infection.
    Lung Cancer. 2019 Jun 17. pii: S0169-5002(19)30511.
    PubMed     Text format    
    
    

    
    Lung Cancer (Auckl)

41. WEINBERG F, Gadgeel S
    Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
    Lung Cancer (Auckl). 2019;10:47-56.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

42. ZHOU L, Jiang Y, Liu X, Li L, et al
    Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappaB-CCL2 signaling in lung cancer.
    Oncogene. 2019 Jun 26. pii: 10.1038/s41388-019-0840.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

43. YIN J, Hu W, Pan L, Fu W, et al
    let7 and miR17 promote selfrenewal and drive gefitinib resistance in nonsmall cell lung cancer.
    Oncol Rep. 2019 Jun 12. doi: 10.3892/or.2019.7197.
    PubMed     Text format     Abstract available
    
    
44. HSU PC, Tian B, Yang YL, Wang YC, et al
    Cucurbitacin E inhibits the Yesassociated protein signaling pathway and suppresses brain metastasis of human nonsmall cell lung cancer in a murine model.
    Oncol Rep. 2019 Jun 20. doi: 10.3892/or.2019.7207.
    PubMed     Text format     Abstract available
    
    
45. CHEN W, Xin B, Pang H, Han L, et al
    Downregulation of estrogen receptor beta inhibits lung adenocarcinoma cell growth.
    Oncol Rep. 2019;41:2967-2974.
    PubMed     Text format     Abstract available
    
    
46. DUAN L, Pang HL, Chen WJ, Shen WW, et al
    The role of GDF15 in bone metastasis of lung adenocarcinoma cells.
    Oncol Rep. 2019;41:2379-2388.
    PubMed     Text format     Abstract available
    
    
47. CHANG CY, Chang SL, Leu JD, Chang YC, et al
    Comparison of cofilin1 and Twist1 protein expression in human nonsmall cell lung cancer tissues.
    Oncol Rep. 2019 Jun 10. doi: 10.3892/or.2019.7193.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

48. RADKIEWICZ C, Dickman PW, Johansson ALV, Wagenius G, et al
    Sex and survival in non-small cell lung cancer: A nationwide cohort study.
    PLoS One. 2019;14:e0219206.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: